
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Ekso Bionics Holdings Inc (EKSO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/02/2025: EKSO (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $6.75
1 Year Target Price $6.75
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.11% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.32M USD | Price to earnings Ratio - | 1Y Target Price 6.75 |
Price to earnings Ratio - | 1Y Target Price 6.75 | ||
Volume (30-day avg) 2 | Beta 0.89 | 52 Weeks Range 2.73 - 19.20 | Updated Date 09/2/2025 |
52 Weeks Range 2.73 - 19.20 | Updated Date 09/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.49 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -75.66% | Operating Margin (TTM) -193.24% |
Management Effectiveness
Return on Assets (TTM) -30.17% | Return on Equity (TTM) -96.44% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9943205 | Price to Sales(TTM) 0.7 |
Enterprise Value 9943205 | Price to Sales(TTM) 0.7 | ||
Enterprise Value to Revenue 0.68 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 2611790 | Shares Floating 2244727 |
Shares Outstanding 2611790 | Shares Floating 2244727 | ||
Percent Insiders 4.95 | Percent Institutions 2.76 |
Upturn AI SWOT
Ekso Bionics Holdings Inc

Company Overview
History and Background
Ekso Bionics Holdings Inc. was founded in 2005 and is based in Richmond, California. It designs, develops, and commercializes exoskeletons for medical and industrial applications. Initially focused on military applications, Ekso Bionics has since transitioned to primarily medical rehabilitation and industrial solutions.
Core Business Areas
- Medical: Designs, develops, and sells exoskeletons for rehabilitation of patients with spinal cord injuries, stroke, and other neurological conditions. Products include the EksoNR.
- Industrial: Develops and sells exoskeletons for use in industrial settings to reduce worker fatigue and injury. Products include the EksoVest.
Leadership and Structure
Scott Davis is the CEO. The company operates with a functional organizational structure across engineering, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- EksoNR: An exoskeleton used in rehabilitation clinics for patients with neurological conditions to regain mobility. Competing products include ReWalk Robotics and Cyberdyne. Market share is estimated around 25% within the rehabilitation exoskeleton market, though precise figures are difficult to obtain.
- EksoVest: An upper-body exoskeleton designed for industrial workers to reduce fatigue and risk of injury during repetitive tasks. Competitors include suitX (now Ottobock) and StrongArm Technologies. Market share data is fragmented and not readily available but estimated around 10-15%.
Market Dynamics
Industry Overview
The exoskeleton market is growing, driven by increasing awareness of the benefits of exoskeletons in rehabilitation and industrial settings. The market is segmented by end-user (medical, industrial, military) and by type of exoskeleton (powered, passive).
Positioning
Ekso Bionics is a key player in the medical and industrial exoskeleton markets, known for its technology and brand recognition. The company is continuously innovating to improve its products and expand its market reach.
Total Addressable Market (TAM)
The TAM for exoskeletons is projected to reach billions of dollars in the coming years. Ekso Bionics is positioned to capture a significant portion of this market through its established products and ongoing innovation. TAM estimates vary widely, but several reports project the global exoskeleton market to reach $2-4 Billion by 2030. Ekso Bionics is striving to capture 10-20% of this growing market.
Upturn SWOT Analysis
Strengths
- Established brand in the exoskeleton market
- Strong technological capabilities
- Focus on both medical and industrial applications
- FDA cleared products
Weaknesses
- Limited financial resources compared to larger competitors
- High product costs
- Dependence on clinical adoption rates
- Lack of consistent profitability
Opportunities
- Expanding applications in new industries
- Partnerships with healthcare providers and industrial companies
- Developing more affordable exoskeleton solutions
- Government funding for exoskeleton research and development
Threats
- Competition from larger, well-funded companies
- Regulatory hurdles
- Slow adoption rates due to high costs
- Technological advancements rendering current products obsolete
Competitors and Market Share
Key Competitors
- REWK
- CYBNY
Competitive Landscape
Ekso Bionics has a strong brand and established products but faces competition from larger, well-funded companies. Ekso Bionicsu2019 advantage lies in its specialized expertise and focus on specific applications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been variable, with periods of rapid growth followed by periods of slower growth. Revenue growth depends on product adoption and market expansion.
Future Projections: Future growth projections would be based on analyst estimates and would be provided if available.
Recent Initiatives: Recent initiatives include expanding sales efforts, developing new exoskeleton models, and pursuing strategic partnerships.
Summary
Ekso Bionics is a key player in the growing exoskeleton market, leveraging its established brand and technological expertise in both medical and industrial sectors. However, the company faces challenges including high product costs, competition from larger entities, and the need for sustained profitability. Strategic partnerships and expansion into new applications are crucial for future growth. Maintaining its technology edge and navigating regulatory hurdles will be essential for success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst estimates
- Press releases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are approximate and may vary depending on the source. Financial data is not current and is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ekso Bionics Holdings Inc
Exchange NASDAQ | Headquaters San Rafael, CA, United States | ||
IPO Launch date 2014-01-16 | CEO & Director Mr. Scott G. Davis | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 61 | Website https://www.eksobionics.com |
Full time employees 61 | Website https://www.eksobionics.com |
Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EVO, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. It also offers EksoCare offering an extended warranty and premium service options, repairs and maintenance services, and training programs. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.